Nature Genetics, 56, 1644-1653. → DOI37: Retinal ganglion cell and microvascular density loss in hereditary spastic paraplegia.Turski, G.N., Turski, C.A., Grobe-Einsler, M., Kobeleva, X., … & Klockgether, T. (2024).
Restorative Neurology and Neuroscience, 41(5-6), 229-239. → DOI36: Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease.Patow, G., Stefanovski, L., Ritter, P., Deco, G., & Kobeleva, X. (for the Alzheimer’s Disease Neuroimaging Initiative) (2023).
Alzheimer's Research & Therapy, 15, 210. → DOI35: Performance evaluation of automated white matter hyperintensity segmentation algorithms in a multicenter cohort on cognitive impairment and dementia.Gaubert, M., Dell’Orco, A., … & DELCODE Study Group (Kobeleva, X. part of DECLODE Study Group) (2023).
Frontiers in Psychiatry, 13, 1010273. → DOI34: Linking early-life bilingualism and cognitive advantage in older adulthood.Ballarini, T., Kuhn, E., Röske, S., … Kobeleva, X., … & DELCODE Study Group (2023).
Neurobiology of Aging, 124, 18-28. → DOI33: Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.Jessen, F., Wolfsgruber, S., Kleineindam, L., … Kobeleva, X., … & Düzel, E. (2023).
Alzheimer's & Dementia, 19(2), 487-497. → DOI32: Midlife occupational cognitive requirements protect cognitive function in old age by increasing cognitive reserve.Kleineidam, L., Wolfsgruber, S., Weyrauch, A.-S., … Kobeleva, X., … & Wagner, M. (2022).
Frontiers in Psychology, 13, 957308. → DOI31: Coherent structural and functional network changes after Nucleus Ventralis Intermedius lesion in Essential Tremor.Pohl, E.*
, Upadhuay, N.*
, Kobeleva, X.*
, … & Boecker, H. (2022).
Movement Disorders, 37(9), 1924-1929. → DOI30: Advancing brain network models to reconcile functional neuroimaging and clinical research.Kobeleva, X., Varoquaux, G., Dagher A., Adhikari, M., Grefkes, C., Gilson, M. (2022).
NeuroImage Clinical, 36, 103262. → DOI29: Adult-Onset Neurodegeneration in Nucleotide Excision Repair Disorders (NERDND): Time to Move Beyond the Skin.Cordts, E., Oender, D., Traschütz, A., Kobeleva, X., … & Deschauer, M. (2022).
Movement Disorders, 37(8), 1707-1718. → DOI28: Revealing the relevant spatiotemporal scale underlying whole-brain dynamics.Kobeleva, X., López-González, A., Kringelbach, M., & Deco, G. (2021).
Frontiers in Neuroscience, 15, 715861. → DOI27: Brain activity is contingent on neuropsychological function in an fMRI study of Verbal Working Memory in Amyotrophic Lateral Sclerosis.Kobeleva, X., Machts, J., Veit, M., Vielhaber, S., Petri, S., & Schoenfeld, M.A. (2021).
European Journal of Neurology, 28(89), 3051-3060. → DOI26: Clinically applicable quantitative magnetic resonance morphologic measurements of grey matter changes in the human brain.Fu, T., Kobeleva, X., Bronzlik, P., Nösel, P., Dadak, M., Lanfermann, H., Petri, S., Ding X. (2021).
Brain Sciences, 11(1), 55. → DOI25: Brainhack: Developing a culture of open, inclusive, community-driven neuroscience.Gau, R., Noble, S., …, Kobeleva, X., … & The Brainhack Community (2021).
Neuron, 109(11), 1769-1775. → DOI24: Centering inclusivity in the design of online conferences—An OHBM–Open Science perspective.Levitis, E., van Praag, CDG, …, Kobeleva, X., … & Maumet, C. (2021).
GigaScience, 10(8), giab051. → DOI23: Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study.Sannemann, L., Schild, A.-K., … Kobeleva, X., … & Jessen, F. (2020).
Alzheimer's Research & Therapy, 12(1), 1-11. → DOI22: Minor neuropsychological deficits in patients with subjective cognitive decline.Wolfsgruber, S., Kleineidam L., … & DELCODE Study Group (Kobeleva, X. part of DECLODE Study Group) (2020).
Neurology, 95(9), e1134-e1143. → DOI21: Bi-allelic HPDL variants cause a neurodegenerative disease ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia.Husain, R.A., Grimmel, A., … Kobeleva, X., … Haack, T.B. (2020).
American Journal of Human Genetics, 107(2), 364-373. → DOI20: Truncating Mutations in UBAP1 Cause Hereditary Spastic Paraplegia.Fard, M. A. F., Rebelo, A. P., Buglo, E., Nemati, H., Dastsooz, H., Gehweiler, I., … Kobeleva, X., … & Cortese, A. (2019).
The American Journal of Human Genetics, 104(4), 767-773. → DOI19: Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.Ludolph, A. C., Schuster, … & RAS-ALS Study Group (Kobeleva, X. part of RAS-ALS Study Group) (2018).
The Lancet Neurology, 17(8), 681-688. → DOI18: Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.Westeneng, H. J., Debray, T. P., Visser, A. E., van Eijk, R. P., Rooney, J. P., Calvo, A., … Kobeleva, X., … & van den Berg, L. H. (2018).
The Lancet Neurology, 17(5), 423-433. → DOI17: Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer’s disease patients.Peraza, L. R., Cromarty, R., Kobeleva, X., Firbank, M. J., Killen, A., Graziadio, S., … & Taylor, J.-P. (2018).
Scientific Reports, 8(1), 4637. → DOI16: Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer’s disease.Kobeleva, X.*
, Firbank, M.*
, Peraza, L., Gallagher, P., Thomas, A., Burn, D. J., … & Taylor, J. P. (2017).
Cortex, 92, 8-18. → DOI15: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.Meininger, V., Genge, A., … & NOG112264 Study Group (Kobeleva, X. part of NOG112264 Study Group) (2017).
The Lancet Neurology, 16(3), 208-216. → DOI14: Forschung für Alle in der Junge-Neurologen-Postersession (in German language).Kobeleva, X. (2017).
NeuroTransmitter, S1/2017, 54. → DOI13: Working memory network changes in ALS: an fMRI Study.Vellage, A. K., Veit, M., Kobeleva, X., Petri, S., Vielhaber, S., & Müller, N. G. (2016).
Frontiers in Neuroscience, 10, 158. → DOI12: Neural correlates of attention‐executive dysfunction in lewy body dementia and Alzheimer’s disease.Firbank, M.*
, Kobeleva, X.*
, Cherry, G., Killen, A., Gallagher, P., Burn, D. J., … & Taylor, J. P. (2016).
Human Brain Mapping, 37(3), 1254-1270. → DOI11: Hilfsmittelversorgung bei der amyotrophen Lateralsklerose (in German language).Funke, A., Grehl, T., Großkreutz, J., Münch, C., Walter, B., Kettemann, D., … Kobeleva, X., … & Meyer, T. (2015).
Der Nervenarzt, 86(8), 1007-1017. → DOI10: International Issues: An international survey of young neurologists’ perceptions of future health care and neurology.Macerollo, A., Róna-Vörös, K., Struhal, W., Kobeleva, X., & Sellner, J. (2015).
Neurology, 84(4), e20-e23. → DOI9: Dissociation of explicit and implicit measures of the behavioral inhibition and activation system in borderline personality disorder.Kobeleva, X., Seidel, E. M., Kohler, C., Schneider, F., Habel, U., & Derntl, B. (2014).
Psychiatry Research, 218(1-2), 134-142. → DOI8: International Issues: Cross-border mobility of junior neurologists within and to the European Union.Macerollo, A., Varga, E. T., Struhal, W., Györfi, O., Kobeleva, X., & Sellner, J. (2014).
Neurology, 83(13), e128-e131. → DOI7: Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.Kobeleva, X., Wegner, F., Brunotte, I., Dadak, M., Dengler, R., & Stangel, M. (2014).
Journal of Neuroinflammation, 11(1), 19. → DOI6: DGN-Kongress 2013. Wo muss ich hin? – Medizin für kluge Köpfe (in German language).Ossig, C., Kobeleva, X., Wilcken, S., Müller, L., Bernhard, F., & Angermaier, A. (2013).
NeuroTransmitter, S1/2013, 50-52. → DOI5: The European Association of Young Neurologists and Trainees in 2013: striking a blow for European junior neurologists.Macerollo, A., Varga, E. T., Györfi, O., Kobeleva, X., Paterson, R. W., & Sellner, J. (2013).
European Journal of Neurology, 20(4), e54-e58. → DOI4: Barriers to novel therapeutics in amyotrophic lateral sclerosis.Kobeleva, X., & Petri, S. (2013).
Neurodegenerative Disease Management, 3(6), 525-537. → DOI3: E-learning preferences of European junior neurologists—an EAYNT survey.Sztriha, L. K., Varga, E. T., Róna-Vörös, K., Holler, N., Ilea, R., Kobeleva, X., … & Sellner, J. (2012).
Frontiers in Neurology, 3, 167. → DOI2: Neurowissenschaften hautnah – als Doktorandin und Famulantin in der Psychiatrie (in German language).Kobeleva, X. (2012).
In Irgendwie kommt es anders: Psychiater erzählen, 133-137. → DOI1: Nachwuchsarbeit 2011 auf nationaler und europäischer Ebene: Die Aktivitäten der Jungen Neurologen und der EAYNT (in German language).Holler, N., Kobeleva, X., Hilienhof, A., Wolz, M., & Sellner, J. (2011).
Aktuelle Neurologie, 38(01), 45-47. → DOI